Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy

Single centre study (n=108) reported improved short‐term efficacy of infliximab treatment with Bayes-based optimised dosing with improved overall clinical remission (65.7% to 80.4%; P < 0.0001) and increased median infliximab trough concentrations (3.21 to 5.13 mg/L; P < 0.0001).

SPS commentary:

Bayes-based optimised dosing is modelā€based dosing of infliximab maintenance treatment.


British Journal of Clinical Pharmacology